News and Trends 2 Jun 2023 Anocca raises $36.6M for large-scale development of cancer cell therapies Anocca AB has raised SEK 400 million ($36.6 million) to further develop the discovery and manufacture of next generation cell therapies for cancer on an industrial scale. It will also allow Anocca to progress its first products into clinical trials. The financing brings together a group of existing and new investors, including Mellby Gård, AMF, […] June 2, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Molecular Partners presenting positive solid tumor data Molecular Partners AG will present additional positive data from the ongoing phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) annual meeting, June 2 to 6 in Chicago, U.S. The […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 Transgene and BioInvent report positive solid tumor results Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, have announced positive phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors. Treatment with single agent […] May 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 FDA approval for Rznomics’ glioblastoma treatment trial Rznomics Inc., a South Korea based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, has received phase 1/2a IND approval from the U.S. FDA for its glioblastoma multiforme (GBM) treatment. RZ-001 initially obtained IND approval for hepatocellular carcinoma (HCC), but Rznomics also found pre-clinical efficacy in GBM models and submitted the IND for […] May 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 Vicore reports new data from idiopathic pulmonary fibrosis study Vicore Pharma Holding AB (publ), has announced an updated interim analysis of its AIR phase 2a trial with C21 in idiopathic pulmonary fibrosis (IPF). With 51 patients enrolled, the data demonstrates that C21 has the potential to transform the treatment of IPF and restore lung function. The disease is currently considered to be incurable and […] May 23, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 Take part in a clinical trial? Sure, just pay me The majority of people in the U.K. (68%) would consider taking part in a clinical trial, it has been revealed today, while half of Brits would also be willing to take part in an early phase clinical trial. Financial payment is the most popular motivation for taking part in a clinical trial, but discovering new […] May 23, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 May 2023 Five recent advancements in arthritis research over the past year Today, more than 350 million people across the world – and nearly a quarter of American adults – have arthritis. A condition characterized by pain, inflammation and stiffness in the joints – often owing to a hyperactive immune system causing the body to attack its own joint tissues, in the case of rheumatoid arthritis – […] May 22, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 19 May 2023Beyond Biotech podcast 46: International Clinical Trials Day This week’s podcast is sponsored by Jubilant Biosys. May 20 is International Clinical Trials Day. ECRIN, the European Clinical Research Infrastructure Network, is a not-for-profit organization that supports the conduct of multinational clinical trials in Europe. Based in Paris, France, the organization launched International Clinical Trials Day (ICTD) in 2005 to commemorate the day when […] May 19, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 Industry responds to UK science strategy launch The UK Health Security Agency’s (UKHSA) has launched a 10-year science strategy, setting out how science can save more lives and contribute to the U.K.’s ambition of being a global science superpower. The strategy sets out how the UKHSA scientific capabilities – including genomics, vaccine evaluation, surveillance, data science, diagnostics and toxicology – will be […] May 18, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 May 2023 Battling food allergies: emerging immunotherapies While for most individuals, picking a restaurant to dine at could simply be based on what they might be craving at the moment, for about one to five per cent of the world’s population, this is a well-thought-out decision that involves ensuring there wouldn’t be any cross-contamination in the food which is bound to trigger […] May 11, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 10 May 2023 Scientists create first CRISPR-based drug candidate targeting the microbiome A new CRISPR-based drug candidate targeting E. coli in the gut microbiome is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections. Many people have experienced infections from E. coli, which are […] May 10, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Promising results from phase 3 prostate cancer study Astellas Pharma Inc. and Pfizer Inc. have announced trial results from a phase 3 study on prostate cancer. The results showed XTANDI (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival (MFS) in men with non-metastatic hormone-sensitive prostate […] May 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email